Greg Meiffren, PhD, is Director of Clinical Development, PKPD and Biology at Adocia (Lyon, France). He joined the company in 2009. He is also project leader on BioChaperone Lispro, an ultra-rapid insulin lispro formulation and BioChaperone Combo, a co-formulation of insulin glargine and insulin lispro. He has supervised 25 clinical trials in the diabetes field on various innovative formulations including ultra-rapid insulins, fixed basal/prandial insulin co-formulations, glucagon and more recently on pramlintide/prandial insulin co-formulations. He is graduated from the Ecole Normale Superieure de Lyon, France, and his PhD focused on differentiation of regulatory T cells and cellular responses to pathogens.